Genprex (NASDAQ:GNPX) has said the active ingredient in immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer (TNBC) by independent researcher.
In a statement on Wednesday, the company noted that a study published in the medical Journal “Nature”, researchers found that TUSC2, the lead component of the drug, acts as a tumor-preventing gene.
The study discovered that MicroRNA-138, a biomarker associated with the particularly aggressive form of breast cancer, targets TUSC2 and restricts it. However, increasing the production of TUSC2 reduces miRNA-138 and frees up TUSC2 to suppress tumors.
Investors took the news and ran with it, bumping Genprex stock nealry 15% higher to $0.99 Wednesday morning.
READ: Genprex unveils anticipated milestones, future guidance on the clinical development programs for its Oncoprex immunogene therapy
“The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” CEO Rodney Varner said in a statement. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”
That’s where Oncoprex, which contains TUSC2, could come in.
The company is currently undergoing clinical and pre-clinical research about the effectiveness of TUSC2 when combined with other therapies and immunotherapies in small-cell lung cancer.
Other data, the company said, indicated TUSC2 may also be effective at combating glioblastoma, head and neck cancer, kidney cancer, and soft tissue sarcomas.
The study was published under the title, “MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression”.
—Updated to include stock movement—
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel